A plain-language guide to understanding care.

What would I actually be paying for?

Ask for the whole bill before agreeing to a plan.

Is there an approved-product price to compare?

FDA stands for Food and Drug Administration. This US agency reviews medicines.

BPC-157 has no approved US product as of September 28, 2026.

That leaves no published price from a maker of an approved product or a government programme.

A number on a care offer cannot fill that gap.

Before agreeing to a plan, ask whether it charges per visit or by a recurring membership.

Ask for a written quote that separates the charges. Keep it until the billing questions are settled.

Visit and follow-up: What does the first visit cost, and what covers later questions?
Tests: Which tests are proposed, why, and who bills for them?
Any medicine: Which medicine is proposed, who supplies it, and is its cost included?
Recurring charges: When does an introductory rate end, and what repeats after that?
Stopping a plan: How do I stop the plan, and what has already been charged?

Ask the insurer about the visit and each test separately. Ask which charges are covered and what stays yours.

Keep the reply with the written quote. If the plan uses a term you do not understand, ask for it in ordinary words.

An insurance plan’s list of covered medicines is called its formulary.

Prior authorization means the insurer needs to agree to pay before the prescription is filled.

These terms describe payment steps. They do not give the proposed drug FDA approval.

As of September 17, 2026, FDA lists unusually low pharmacy prices as a warning sign.

Legitimate cash prices can also be low. Use that sign together with the other checks.

Read price claims alongside licence checks and product status.

A written price is useful. It is not evidence that a treatment works.